- Home
- EDU vs ARWR Comparison
EDU vs ARWR Comparison
Compare EDU & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDU | ARWR |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 9.4B |
| IPO Year | 2006 | 1993 |
Fundamental Metrics
Financial Performance| Metric | EDU | ARWR |
|---|---|---|
| Price | $57.54 | $67.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $62.80 | ★ $77.55 |
| AVG Volume (30 Days) | 659.2K | ★ 2.5M |
| Earning Date | 01-28-2026 | 02-05-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.27 | N/A |
| Revenue | ★ $4,987,826,000.00 | $829,448,000.00 |
| Revenue This Year | $10.91 | N/A |
| Revenue Next Year | $10.38 | N/A |
| P/E Ratio | $25.46 | ★ N/A |
| Revenue Growth | 7.29 | ★ 23258.15 |
| 52 Week Low | $40.66 | $9.57 |
| 52 Week High | $61.56 | $76.76 |
Technical Indicators
Market Signals| Indicator | EDU | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 56.27 | 54.99 |
| Support Level | $53.80 | $61.65 |
| Resistance Level | $60.06 | $68.24 |
| Average True Range (ATR) | 1.36 | 3.97 |
| MACD | -0.20 | -0.37 |
| Stochastic Oscillator | 59.42 | 42.57 |
Price Performance
Historical ComparisonAbout EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.